[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636563":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":28,"collaborators":11,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":11,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":11,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immunotherapy group","ACTIVE_COMPARATOR",null,[13],"Drug: Immunotherapy group",{"label":15,"type":16,"description":11,"interventionNames":17},"Immunotherapy combined with interventional therapy group","EXPERIMENTAL",[18],"Procedure: Immunotherapy combined with interventional therapy group",[20,24],{"type":21,"name":15,"description":22,"armGroupLabels":23,"otherNames":11},"PROCEDURE","Tislelizumab 200mg, intravenous infusion, every 3 weeks, for 2 years. Simultaneously, the patient undergoes 1-3 sessions of transbronchial chemoembolization (BACE). A follow-up enhanced CT scan of the lungs and mediastinum is performed 4-6 weeks after BACE. Based on the results, the investigator will assess whether further BACE is necessary, with a maximum of 3 BACE sessions per patient.",[15],{"type":25,"name":9,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","Tislelizumab 200 mg, IV infusion, Q3W, maintenance for 2 years. Follow up with enhanced CT scans of the lungs and mediastinum every 4-6 weeks, and assess efficacy according to RECIST 1.1 criteria.",[9],{"type":29,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100636563","phase-4-stage-iv-lung-squamous-cell-carcinoma-treated-with-or-without-bronchial-artery-chemoembolization-after-first-line-chemotherapy-and-immunotherapy-100636563",false,"NCT07567313","Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy","Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study of Patients With Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy","Inclusion Criteria:\n\n1. Squamous cell carcinoma of the lung confirmed by histology or cytology;\n2. According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.\n3. Has received standard first-line chemotherapy immunotherapy for 4\\~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;\n4. The patient is 18-80 years old;\n5. ECOG PS score is 0-1;\n6. The main organ functions meet the following criteria: (1) Blood routine examination: hemoglobin (HB) ≥ 90g\u002FL; Leukocyte (ANC) ≥ 3.0× 109\u002FL; Neutrophils ≥ 1.5× 109\u002FL; Platelet (PLT) ≥ 75× 109\u002FL; (2) Biochemical examination: albumin (ALB)≥29g\u002FL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2uln; Total bilirubin (TBIL) ≤ 1.5 ULN; Creatinine ≤ 1.5 ULN;\n7. Patients and\u002For their families agree to participate in clinical trials and sign informed consent forms;\n8. No history of other malignant tumors;\n9. No active infection;\n10. Be able to cooperate with research follow-up;\n11. At least one measurable lesion (according to RECIST 1.1);\n12. The expected survival time is more than 3 months.\n\nExclusion Criteria:\n\n1. There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;\n2. Have a history of allergy to contrast agents or chemotherapy drugs;\n3. Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;\n4. Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);\n5. Coagulation function is seriously abnormal and cannot be corrected;\n6. Hypertension patients still have poor blood pressure control (systolic blood pressure \\> \\>160mmHg, diastolic blood pressure \\> 100 mmhg) after antihypertensive drugs treatment;\n7. Pregnant or lactating female patients;\n8. Have a history of mental illness or psychotropic drug abuse;\n9. Patients with symptomatic brain metastasis;\n10. Patients with autoimmune diseases;","ALL","18 Years","80 Years",{"count":41,"type":42},166,"ESTIMATED","INTERVENTIONAL",[45],"PHASE4","This study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoembolization for stage IV lung squamous cell carcinoma.",[48],"Lung Squamous Cell Carcinoma Stage IV",[50,51],"quamous cell carcinoma of the lung","interventional bronchial artery chemoembolization","NOT_YET_RECRUITING","2026-05-03",{"date":55,"type":56},"2026-05-05","ACTUAL",{"date":58,"type":42},"2026-04-20",{"date":60,"type":42},"2028-06-30",{"name":5,"class":6}]